exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089022 RNA Name: hsa-miR-519c-3p RNA Type: miRNA Chromosome: chr19 Starnd: + Coordinate: Start Site(bp): 53686522 End Site(bp): 53686543 External Links: hsa-miR-519c-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ADAR chr1 154582057 154628013 - ARL4A chr7 12686856 12690958 + CCDC93 chr2 117915478 118014133 - CCSAP chr1 229321011 229343294 - CHD9 chr16 53055033 53329150 + CLCN6 chr1 11806096 11848079 + CLIP4 chr2 29097705 29189643 + EEA1 chr12 92770637 92929331 - EIF5A2 chr3 170888418 170908644 - FAM13A chr4 88725955 89111398 - JPT1 chr17 75135248 75168281 - KLHL28 chr14 44924319 45042322 - MAGI3 chr1 113390515 113685923 + MTF1 chr1 37809574 37859592 - NPAS2 chr2 100820139 100996829 + RCCD1 chr15 90954870 90963125 + SEC16A chr9 136440096 136483759 - SLC16A14 chr2 230034982 230068993 - SLC46A3 chr13 28700064 28718970 - SMAD7 chr18 48919853 48952052 - SYAP1 chrX 16719612 16765340 + TAOK3 chr12 118149801 118372907 - TMEM50A chr1 25338317 25362361 + ZFAND4 chr10 45615500 45672780 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001495 chr5 68470703 68471364 + hsa_circ_0000494 chr13 76134888 76143643 + hsa_circ_0000018 chr1 15860731 15863309 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC002094.1 chr17 28357647 28381697 + AC010542.4 chr16 66549280 66551189 + AC015871.3 chr15 79920195 79922455 - AC021078.1 chr5 149494314 149504670 - AC021092.1 chr19 44103007 44113183 - AC024940.6 chr12 31280422 31280895 - AC087477.2 chr15 96354237 96405235 + AC243964.3 chr19 44631573 44725217 - AL137782.1 chr13 75549773 75807120 + AL158206.1 chr9 19453209 19455173 + CKMT2-AS1 chr5 81201341 81301565 - EPB41L4A-AS1 chr5 112160526 112164818 + ERICD chr8 140636281 140638283 + H19 chr11 1995176 2001470 - HAGLR chr2 176164051 176188958 - HOTAIR chr12 53962308 53974956 - MAGI2-AS3 chr7 79452877 79471208 + MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.